BioRestorative Therapies price to sales ratio BRTX

Market value divided by revenue over the last twelve months, since 2014.

Today, Oct 23, 2026: 5.8×
10-year median: 53.5×
Against its 10-year history: 17th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.0× to 199×
Peer median: 0.4×

BioRestorative Therapies' price to sales ratio is 5.8× as of Oct 23, 2026.

That is below its ten-year median of 53.5×, lower than on 83% of days in the last ten years.

Over that time it ranged from 0.0× in Apr 2020 to 199× in Jan 2022.

The median for 7 healthcare stocks of a similar size is 0.4×.

Price to sales ratio over time

median 53.5×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	5.8×	4.9×	34.0×
2025	25.9×	18.1×	43.7×
2024	28.5×	26.6×	101×
2023	62.9×	59.9×	180×
2022	83.4×	83.4×	199×
2021	94.9×	1.7×	191×
2020	1.7×	0.0×	8.1×
2019	1.9×	1.9×	112×
2018	69.7×	61.9×	190×
2017	83.4×	69.5×	93.4×
2016	65.6×	19.0×	65.6×
2015	26.1×	15.0×	44.2×
2014	46.8×	33.7×	59.2×

Against its peers

Companies in Healthcare nearest BioRestorative Therapies' size, closest first, today.

Company	Price to sales ratio
BRTXBioRestorative Therapies	5.8×
OXBROXBRIDGE RE HOLDINGS	2.8×
EDUCEducational Development	0.4×
GTIMGood Times Restaurants	0.1×
MDRRMedalist Diversified	1.6×
BCGBinah Capital	0.1×
VIPVulcan Infrastructure & Power	0.4×
MXCMexco Energy	3.0×
Peer median	0.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on BioRestorative Therapies

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.